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Objectives: 
 
to investigate whether in-ambulance abciximab initiation, in
ST-elevation myocardial infarction (STEMI) patients improves ST segment
resolution (STR) after primary percutaneous intervention (PCI).
 
Methods:
 
 MISTRAL is a prospective randomized double blind study con-
ducted in 11 centers in France (ClinicalTrial.gov number NCT 00638638). 256
patients with STEMI within 6 hours from symptom onset were allocated to
receive Abciximab started either in the Mobile Intensive Care Unit (MICU) or
later in the cathlab after diagnostic angiography. Other treatments in the MICU
included aspirin 250 mg IV, heparin 40 UI/kg IV. Primary endpoint was com-
plete (>70%) ST-segment resolution was adjudicated by an independent cen-
tralized ECG-Corelab.
 
Results: 
 
 mean age was 56 ± 12 years old and 80 % of the patients were
males. Median delay from symptoms to diagnosis was 90 min and 103 min
min from diagnosis to balloon. Complete ST resolution was similar in the
early and late groups 21% vs 15% (p=0.44) before PCI and 70 % vs 67%
(p=0.67) 60 min after PCI. Mean residual ST elevation tended to be lower in
the early group before PCI 8.1 vs 9.6 mm (P=0.17) but not after PCI 3.0 vs
3.2 mm (p=0.62). In the early group, TIMI 2-3 flow rate before PCI tended to
be higher (45 vs 34%, p=0.095 ) and distal embolisation rate was lower (8 vs
21%, p=0.008). TIMI 2-3 flow rate post-PCI, blush score rates, LVEF, bio-
logic infarct size, 30 days MACE were similar in both groups with very low
mortality rates (1.7 vs 0.8%).
 
Conclusions:
 
 early ambulance vs. routine cathlab administration of abcix-
imab in STEMI did not improve ST resolution post-PCI, final TIMI flow rate,
LVEF, infarct size and MACE. Early ambulance abciximab tended to improve
TIMI 2-3 flow rates pre-PCI and to reduce slow flow and distal embolisation
during procedure. Early abciximab tends to “facilitate” PCI procedure since
more arteries are opened at the time of angio (45 vs 34 % TIMI2-3) and less
embolisation or slow flow occurs during procedure.
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Iron deficiency in non-anemic heart failure patients.
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Background:
 
 Functional improvement has recently been reported in
anemic and non-anemic heart failure (HF) patients with biological iron defi-
ciency who were treated by intravenous iron substitution. Our aim was to
show whether the non-anemic patients with iron deficiency have poorer func-
tional tests than non-deficient ones. 
 
Method:
 
 We included 138 HF patients without anemia from our HF
department at Toulouse University Hospital into 2 groups: 1/ low ferritin rate
group (LFG) with a serum ferritin of 100 µg/L and lower (n=42), 2/  normal
ferritin rate group (NFG) with serum ferritin over 100 µg/L (n=96). We mea-
sured standard blood tests and functional parameters including NYHA status,
6 minute walk test (6’WT), and peak oxygen consumption (VO2max).
 
Results:
 
 Baseline patient characteristics showed a slight difference for
hemoglobin in non-anemic patients (LFG, 13.9; NFG, 14.4; p=0.04) who have
no difference for ejection fraction (LFG, 27.5%; NFG 29.5%; p=NS) between
groups. The iron deficient patients tend to be older (59 versus 63 yo, p=NS)
and most of them were women (92% in LFG versus 67% in NFG (p<0.05)). 
Functional parameters showed i) NYHA status of 2.29 in LFG versus 2.35
in NFG (p=NS); ii) 6’WT of 307m in LFG versus 361m in NFG (p=0.006);
and, iii) VO2max of 13.8ml/min/kg in LFG versus 15.7ml/min/kg for the NFG
(p=0.04). Moreover, the LFG had a higher creatinin rate of 145 µmol/l versus
107µmol/l for the NFG (p= 0.02).
 
Conclusion:
 
 Iron deficient patients have poorer functional tests and are
more likely to have renal insufficiency. Risk factors for iron deficiency in HF
are the age and the female sex. We put in light some risk factors for iron defi-
ciency that may help the practitioner making out which non-anemic HF
patients should have blood tests to look for iron deficiency.
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Purpose:
 
 When isolated and non immune, prevalence of congenital and
childhood atrioventricular blocks (AVB) is extremely low and little is known
about their natural history.
 
Methods:
 
 a multicentric study retrospective from 1980 to 2009 allowed
inclusion of 141 children from 13 French referral centers. Included children
presented an AVB diagnosed in utero, at birth or during childhood before the
age of 15 years, without structural heart abnormalities and without maternal
antibodies.
 
Results:
 
 26 congenital and 114 childhood AVB were included. Symptoms
lead to diagnosis in 15,6% whereas AVB was asymptomatic in 84,4%. 73%
AVB were complete and 26,2% AVB were incomplete at first presentation. 21
of these incomplete blocks (56,7%) progressed to permanent complete AVB.
Narrow QRS complexes were found in 69,2% congenital and 91,2% childhood
AVB. In the 112 (79,4%) implanted children, mean duration between AVB
diagnosis and pacemaker implantation was 35 months. Pacemaker primo-
implantation occurred during the first year of life for 18 children and 90 chil-
dren (63.8%) were paced before 10 years old. Pacing was required for symp-
tomatic bradycardia in 37,5% whereas prophylactic cardiac pacing accounted
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for 61,6%. The median follow-up was 96 months (from 6 to 384 months).
85,1% experienced no complication and neither dilated cardiomyopathy nor
death had occurred at last follow-up. Pacemaker-related complications
appeared in 11,6%.
 
Conclusion:
 
 We describe the largest reported experience with isolated and
non immune congenital and childhood AVB. Such a block is a nodal damage
from unknown origin that may postnatally progress in incomplete forms. Out-
come is not influenced by age at diagnosis. Prognosis is very good with no
late-onset dilated cardiomyopathy, a few pacemaker-related complications in
the modern technological era and no death at last follow-up.
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Background:
 
 Acute Aortic syndromes (AAS) are life threatening diseases.
Despite recent improvement in management, data are limited regarding their
actual diagnosis accuracy, therapeutic and mortality. We aimed to assess deter-
minants of in-hospital mortality in patients with AAS.
 
Method:
 
 Our analysis was based on data from the French prospective
National Multicentre Registry (14 referral French Health Care Centers) of
AAS (Feb 2008 - Dec 2009). Assessment of determinants of in-hospital mor-
tality was based on multivariable logistic regression.
 
Results:
 
 The study included 278 patients (72 % men) mean aged 66 (± 14)
years. AAS consisted in type A dissection (AD; n=143), type B dissection
(BD; n=90), intra mural hematoma (IMH; n=21), complicated thoracic aneu-
rysm (CTA; n=20) and penetrating ulcer (PU; n=4). Major aortic complica-
tions were cardiogenic shock and visceral malperfusion in 14.3 % (n=40) and
13.6 % patients (n=38) respectively. Disease management was medical in 35
% patients, surgery (45 %) or endovascular treatment (13 %). Total intrahos-
pital mortality was 21 % (n=56) [40% in CTA group, 27% in AD group, 16
% in IMH group, 9% in BD group and none in PU group (p=0.001)]. Deter-
minants independently associated with in-hospital mortality were: type of
AAS (Odds ratio= 0.34 [95% confidence interval: 0.14-0.86] for BD, OR=
1.38 [0.45-4.22] for CTA and OR= 0.46 [0.12-1.79] for IMH or PU, versus
type A dissection), age above to 65 years (OR: 2.73 [1.33-5.61]), history of
hypertension (OR: 0.43 [0.21-0.86]), history of aneurysm (OR: 2.47 [1.04 -
5.88]), cardiogenic shock (OR=2.71 [1.18-6.24]) and visceral malperfusion
syndrome (OR=2.42 [1.01-5.78]).
 
Conclusion: 
 
Despite recent progress in diagnostic and therapeutic, acute
aortic syndromes are still associated with high intrahospital mortality. This
recent large multicentric study identifies higher risk patients of poor in-hos-
pital prognosis and emphasizes the need to still improve the management of
AAS.
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Introduction:
 
 Familial amyloid polyneuropathy (FAP) is an autosomic
dominant inherited disease. FAP cardiopathy is characterized by conduction
disorders, denervation, and cardiac infiltration. Because of the risk of high
degree atrioventricular (AV) block and sudden death, prophylactic pacing can
be suggested when there is evidence of amyloid infiltration of the AV conduc-
tion pathways. Our purpose was to estimate prevalence of AV block and
pacing dependence for high risk FAP patients. 
 
Methods:
 
 In a cohort of 51 FAP patients, we performed standard ECG and
electrophysiological study. Patients  with conduction disorders  underwent
prophylactic pacing. During follow up, AV conduction was studied by using
data from the Holter memories of pacemakers. 
 
Results:
 
 Baseline characteristics of the patients are summarized on table 1.
During the follow up, permanent high degree AV block occurred in 23.5% of
the patients (12/51)(cf. fig.1). Average percentage was 23±35 % for ventric-
ular pacing and 18±24% for atrial pacing. Paroxystic AV block was recorded
for all patients but 3 (94%). Prevalence of AV conduction disorders was
283±465 events per month (epm) and was distributed in 14±46 epm for third
degree AV block, 195±386 epm for second degree AV block, 73±225 epm for
first degree AV block and 0.2±0.7 epm for pauses. During the study, sustained
atrial arrhythmias occurred in three patients. No sustained ventricular
arrhythmia was recorded.
 
Conclusions:
 
 Patients with FAP cardiomyopathy present high incidence of
AV blocks. For FAP patients with involvement of the AV conduction
pathway, prophylactic pacemaker insertion should be performed.
 
Incidence of permanent AV block.
Table 1 : Baseline characteristics
 
 Mean±SD
age (years)
 
54±13
 
% of men
 
64.7%
 
Lenght of fu (months)
 
34±33
 
% Val30Met
 
64%
 
Surface ECG
Conduction disorders
 
74%
 
AVB type 1
 
38%
 
PR interbal (ms)
 
191±41
 
QRS interval (ms)
 
94±21
 
Electrophysiological study
corrected sinus recovery time (ms)
 
546±438
 
AH interval (ms)
 
117±43
 
HV interval (ms)
 
68±11
 
Anterior Wenckebach point (bpm)
 
128±33
